OPKO Health, Inc. (NASDAQ:OPK) Receives $2.75 Consensus Price Target from Analysts

Shares of OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) have earned a consensus rating of "Buy" from the five research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $2.75.

A number of research analysts recently issued reports on OPK shares. Barrington Research reiterated an "outperform" rating and set a $2.25 price objective on shares of OPKO Health in a report on Thursday, May 1st. HC Wainwright reiterated a "buy" rating and set a $3.00 target price on shares of OPKO Health in a research note on Monday, April 7th. Wall Street Zen downgraded OPKO Health from a "hold" rating to a "sell" rating in a research note on Monday, May 5th. JPMorgan Chase & Co. assumed coverage on OPKO Health in a research note on Friday, April 25th. They issued a "neutral" rating for the company. Finally, LADENBURG THALM/SH SH raised OPKO Health to a "strong-buy" rating in a report on Tuesday, July 8th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Oak Thistle LLC bought a new stake in shares of OPKO Health in the 1st quarter valued at about $26,000. GM Advisory Group LLC bought a new stake in shares of OPKO Health in the 1st quarter valued at about $33,000. Cerity Partners LLC bought a new stake in shares of OPKO Health in the 1st quarter valued at about $36,000. Wealth Enhancement Advisory Services LLC grew its position in shares of OPKO Health by 75.3% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company's stock valued at $42,000 after buying an additional 12,417 shares during the last quarter. Finally, Pallas Capital Advisors LLC bought a new stake in shares of OPKO Health in the 1st quarter valued at about $43,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health Trading Down 0.7%

NASDAQ OPK traded down $0.01 on Thursday, reaching $1.35. The company had a trading volume of 1,758,039 shares, compared to its average volume of 3,877,104. The stock's 50 day moving average is $1.32 and its 200-day moving average is $1.49. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -19.28 and a beta of 1.34. The company has a quick ratio of 2.28, a current ratio of 2.49 and a debt-to-equity ratio of 0.25. OPKO Health has a 52 week low of $1.21 and a 52 week high of $2.04.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.03). OPKO Health had a negative return on equity of 2.85% and a negative net margin of 5.66%. The business had revenue of $149.90 million during the quarter, compared to the consensus estimate of $163.13 million. During the same quarter last year, the company earned ($0.12) earnings per share. The firm's revenue was down 13.7% compared to the same quarter last year. Equities analysts predict that OPKO Health will post -0.25 earnings per share for the current year.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.